What is PsiThera?
PsiThera operates at the intersection of biophysics, computational modeling, and mechanistic biology. The company is dedicated to transforming the treatment paradigm for immune and inflammatory diseases by developing oral drugs that replace traditional injectable therapies. By harnessing biologically relevant protein states, PsiThera's expert team identifies and optimizes high-value therapeutic targets, with an initial focus on the Tumor Necrosis Factor (TNF) superfamily. This computational-first approach allows for a more agile drug discovery process, potentially reducing the time and cost associated with bringing novel treatments to market.
How much funding has PsiThera raised?
PsiThera has raised a total of $47.5M across 1 funding round:
Series A
$47.5M
Series A (2025): $47.5M with participation from Roivant Sciences, Samsara BioCapital, Lightstone Ventures, and Eurofarma
Key Investors in PsiThera
Roivant Sciences
A tech-enabled healthcare organization that specializes in the development of late-stage drug candidates and the deployment of innovative medical technologies.
Samsara BioCapital
A venture firm focused on creating transformative therapeutics through partnerships with scientists and drug developers to drive biopharmaceutical breakthroughs.
Lightstone Ventures
An investment firm that provides capital and strategic guidance to founders translating cutting-edge scientific research into viable medical therapies.
What's next for PsiThera?
With the infusion of $47.5M, PsiThera is expected to scale its internal drug discovery pipeline and advance its lead candidates toward clinical trials. The strategic focus will likely remain on refining its computational intelligence platform to identify additional targets within the TNF superfamily and beyond. Furthermore, the company is poised to strengthen its operational infrastructure, ensuring that its research capabilities can support the rigorous demands of late-stage drug development. As the firm matures, the integration of these computational insights into clinical practice will be the primary metric for long-term value creation in the competitive biotech sector.
See full PsiThera company page
